Regulatory News :
NEW BRIGHTON, Minnesota -- (BUSINESS WIRE) -- Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering specialist, today announced the attainment of an important milestone in its collaboration with Medicago Inc. (Quebec City, Canada). In January 2012 Cellectis and Medicago entered into a research agreement to improve therapeutic proteins expressed from tobacco leaves.
At this point, the intended modifications of all targeted genes have been obtained and the 8 edited alleles are assembled in a Nicotiana benthamiana plants without detectable morphological or growth defects. Medicago retains non-exclusive and exclusive rights on the production and commercialization of certain biologics. Cellectis retains sub-licensing rights on this bioproduction tool.
Luc Mathis, CEO of Cellectis plant sciences commented: "The assembly, in plants, of mutations in all 8 targeted alleles – in less than 2 years – further proves the efficacy of our synthetic biology platform for the Plant Biotech industry. With the cost of biologics drugs becoming an issue for the healthcare industry, we are proud to have developped with Medicago a competitive bioproduction tool that we intend to make broadly available."
Andy Sheldon, President and CEO of Medicago said: "I congratulate Cellectis plant sciences for the achievement of this milestone and look forward to ongoing collaboration."
About Cellectis plant sciences
Established in March 2010, Cellectis plant sciences is a subsidiary of Cellectis (Alternext: ALCLS) dedicated to the applications of nucleases in plants. Its main mission is to increase and accelerate usage of Cellectis’s proprietary technology in agricultural biology, broaden the company’s platform to attract new and expanded licensing opportunities and explore the development of proprietary traits for selected applications. Cellectis plant sciences is located in New Brighton, Minnesota, USA. Professor Daniel Voytas, Chief Scientific Officer of Cellectis plant sciences, is also Director of the University of Minnesota Center for Genome Engineering. For further information please visit our website: www.cellectis.com
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.